Innate Pharma (IPHA) Return on Sales (2020 - 2024)

Innate Pharma (IPHA) has 5 years of Return on Sales data on file, last reported at 0.04% in Q4 2024.

• For the quarter ending Q4 2024, Return on Sales fell 4.0% year-over-year to 0.04%; the trailing twelve-month figure through Dec 2024 stood at 0.01% (down 1.0% YoY), and the FY2022 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q4 2024 stood at 0.04%, down from 0.03% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q2 2023 and bottomed at 0.04% in Q4 2024.
• The 5-year median for Return on Sales is 0.0% (2023), against an average of 0.01%.
• The widest annual swing landed in 2021, when Return on Sales gained 1 bps; it then slipped 4 bps in 2024.
• A 5-year view of Return on Sales shows it stood at 0.01% in 2020, then soared by 74 bps to 0.0% in 2021, then jumped by 100 bps to 0.0% in 2022, then slumped by 6421288 bps to 0.0% in 2023, then sank by 2587 bps to 0.04% in 2024.
• The last three Return on Sales figures came in at 0.04% (Q4 2024), 0.03% (Q2 2024), and 0.0% (Q4 2023), per Business Quant data.

Peer Comparison